On January 6, 2025, IceCure Medical Ltd. announced it received a notification letter from Nasdaq Stock Market LLC, confirming that the company has regained full compliance with the minimum bid price requirement. This requirement is set forth in Nasdaq Listing Rule 5550(a)(2). The company's ordinary shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days prior to the date of the notice.
This notification signifies that the prior bid price deficiency matter is now closed, and IceCure Medical is in full compliance with all Nasdaq continued listing requirements. The company will continue to be listed and traded on The Nasdaq Capital Market. Regaining compliance removes a significant regulatory concern that could have impacted investor confidence and the company's ability to access capital markets.
The resolution of this compliance issue ensures IceCure's continued presence on a major U.S. stock exchange, providing stability and visibility for its shareholders. This development allows the company to focus its efforts on advancing its cryoablation technology and commercialization strategies without the distraction of potential delisting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.